FSSAI Cracks Down on Nestle and Zydus Over Health Claims
The Food Safety and Standards Authority of India recently initiated action regarding FSSAI misleading health claims against top nutritional brands. Specifically, the food regulator served show-cause notices to Nestle India and Zydus Wellness over unsubstantiated label assertions. Consequently, regulatory bodies have intensified their scrutiny of pediatric food marketing across India.
Scrutiny of Infant Nutrition and Digestive Assertions
First, FSSAI questioned promotional claims on Nestle India's infant formulas, including Lactogen Pro 1 and Nan Excella Pro Stage 1. The authority challenged the assertion that whey protein promotes easy digestion without validated scientific proof. Furthermore, officials flagged claims regarding five human milk oligosaccharides supporting normal immune function. According to current Indian regulations, manufacturers cannot imply that products prevent or treat specific physiological conditions without statutory approval.
FSSAI Misleading Health Claims and Pediatric Growth Claims
In addition, the regulator issued a notice to Zydus Wellness regarding its popular malt-based drink, Complan. The brand advertised slogans such as "grow taller faster" alongside claims of "clinically proven 2X growth." Moreover, the packaging asserted benefits for concentration, memory, and specialized immunity with 34 vital nutrients. Therefore, FSSAI demanded robust clinical evidence from Zydus to justify each marketing statement.
Enforcement Against Social Media Infant Formula Promotions
Meanwhile, digital marketing practices have faced direct regulatory intervention under infant feeding laws. The FSSAI issued notices to several formula makers and an Instagram influencer over unauthorized promotional reels. Notably, the viral video ranked five commercial infant formulas while citing cognitive and immune benefits. However, India's Infant Milk Substitutes Act strictly prohibits direct or indirect promotion of formula products to the public. Thus, authorities maintain strict boundaries to safeguard exclusive breastfeeding and infant health across the country.
Clinical Takeaways for Healthcare Practitioners
As a result, healthcare professionals must critically evaluate commercial nutritional claims before guiding patients. Clinicians should reinforce exclusive breastfeeding for the first six months of life as the gold standard. In contrast, processed health drinks often contain high sugars and lack genuine developmental advantages over whole foods. Consequently, doctors play a central role in debunking misleading advertisements for anxious parents.
Frequently Asked Questions
Q1: Why did FSSAI issue notices to Nestle India over its infant formulas?
FSSAI challenged unverified digestive claims regarding whey protein in Lactogen Pro 1 and immune support claims for HMOs in Nan Excella Pro Stage 1 under food safety advertising regulations.
Q2: What marketing claims for Complan are under investigation?
The regulator flagged promotional claims asserting "2X growth," "grow taller faster," memory enhancement, and specific immune benefits, demanding scientific justification from Zydus Wellness.
Q3: How does Indian law regulate the online promotion of infant milk substitutes?
Under the Infant Milk Substitutes (IMS) Act and FSSAI rules, commercial advertising or influencer promotion of infant formula is strictly prohibited to protect and support breastfeeding.
References
- FSSAI issues notices to Nestle, Zydus over 'misleading' claims - ETHealthworld
- The Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992 (amended 2003) - Ministry of Health and Family Welfare, Government of India
- Food Safety and Standards (Advertising and Claims) Regulations, 2018 - Food Safety and Standards Authority of India (FSSAI)
